Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

These five-year bimekizumab-bkzx results provide valuable evidence for clinical decision-making," said Andrew Blauvelt, MD, MBA, Chair, Medical Board, National Psoriasis Foundation. "The sustained ...

today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.

Pennsylvania School Boards Association member outreach manager-west Lena Hannah honored Geoff Barnes for his five years of service and Gianni ... 20 years receive a plaque.

These five-year bimekizumab-bkzx results provide valuable ... adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis ...